| Dr Ian Denison Schnadig, MD | |
|
19260 Sw 65th Ave, Suite 435, Tualatin, OR 97062-5701 | |
| (503) 692-2032 | |
| (503) 692-4450 |
| Full Name | Dr Ian Denison Schnadig |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 22 Years |
| Location | 19260 Sw 65th Ave, Tualatin, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467664839 | NPI | - | NPPES |
| 2005439 | Medicaid | WA | |
| 500618430 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD150796 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Legacy Meridian Park Medical Center | Tualatin, OR | Hospital |
| Providence St Vincent Medical Center | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Cancer Specialists Pc | 8426943838 | 61 |
| Northwest Cancer Specialists Pc | 8426943838 | 61 |
News Archive
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment - and breast cancers with higher CK5 expression have poorer prognosis.
Trachoma, which is caused by ocular infection with Chlamydia trachomatis, remains the leading infectious cause of blindness and in 2002 was responsible for 3.6% of total global blindness.
Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.
Studying the gene-expression profiles of patients with colorectal cancer might help predict their response to chemotherapy.
› Verified 8 days ago
| Entity Name | Northwest Cancer Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407828114 PECOS PAC ID: 8426943838 Enrollment ID: O20040217000848 |
News Archive
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment - and breast cancers with higher CK5 expression have poorer prognosis.
Trachoma, which is caused by ocular infection with Chlamydia trachomatis, remains the leading infectious cause of blindness and in 2002 was responsible for 3.6% of total global blindness.
Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.
Studying the gene-expression profiles of patients with colorectal cancer might help predict their response to chemotherapy.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ian Denison Schnadig, MD 19260 Sw 65th Ave, Suite 435, Tualatin, OR 97062-5701 Ph: (503) 692-2032 | Dr Ian Denison Schnadig, MD 19260 Sw 65th Ave, Suite 435, Tualatin, OR 97062-5701 Ph: (503) 692-2032 |
News Archive
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment - and breast cancers with higher CK5 expression have poorer prognosis.
Trachoma, which is caused by ocular infection with Chlamydia trachomatis, remains the leading infectious cause of blindness and in 2002 was responsible for 3.6% of total global blindness.
Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.
Studying the gene-expression profiles of patients with colorectal cancer might help predict their response to chemotherapy.
› Verified 8 days ago
Jaymee E Delaney, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 19260 Sw 65th Ave, Ste 270, Tualatin, OR 97062 Phone: 503-352-0770 | |
Jessica Kazue Haraga, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 19250 Sw 90th Ave, Tualatin, OR 97062 Phone: 503-692-3750 Fax: 503-691-2324 | |
Dr. Benito G Pataroque, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 6485 Sw Borland Rd, Suite D, Tualatin, OR 97062 Phone: 503-692-3647 Fax: 503-691-1670 | |
Dr. Tammi Kaye Boston, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 19875 Sw 65th Ave, Suite 100, Tualatin, OR 97062 Phone: 503-692-7785 Fax: 503-885-1663 | |
Dr. William H Treuhaft, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 6485 Sw Borland Rd, Suite F, Tualatin, OR 97062 Phone: 503-413-3650 Fax: 503-413-3644 | |
Dean Kyle Peterson, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 19300 Sw 65th Ave, Tualatin, OR 97062 Phone: 503-413-8407 Fax: 503-413-6951 | |
Dr. Mark Leo Mckinstry, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 19875 Sw 65th Ave, Tualatin, OR 97062 Phone: 503-692-7785 Fax: 503-885-1663 |